Thixotropic Suspension for Personalized Pharmaceutical Dosing
Solution Overview
Problem
The healthcare system faces challenges with prescription non-adherence and 'one size fits all' pharmaceutical formulations, leading to the 'pill burden' problem, which is exacerbated in populations like pediatrics and geriatrics, resulting in significant adverse outcomes.
Innovation Solution
A thixotropic suspension comprising active ingredients is used to create personalized nutritional and pharmaceutical formulations, dispensed as a line on an edible solid substrate, utilizing a computer-controlled dispenser to ensure precise dosing and stability, with a carrier medium that returns to a semi-solid state at rest and liquifies under pressure, and is coated to prevent interaction with the substrate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional fixed-dose pills and liquids are prescribed to patients, then pharmaceutical treatment can be provided, but prescription non-adherence and pill burden increase, especially in pediatrics and geriatrics populations
Solution Approach 1:
The patent divides pharmaceutical treatment into multiple dosage forms (solid substrate, liquid suspension, combination products) that can be tailored to individual patient needs. This segmentation allows customization of dose strength, frequency, and formulation type to match patient preferences and physiological characteristics, thereby improving adherence while reducing perceived pill burden.
Solution Approach 2:
The invention changes key parameters of pharmaceutical delivery including dose concentration, formulation viscosity (thixotropic properties), and physical state (solid/liquid combinations). These parameter changes enable creation of personalized formulations that are easier to administer to pediatric and geriatric populations, directly addressing adherence and ease of operation concerns.
2Ease of manufacture
If one size fits all pharmaceutical formulations are used, then manufacturing is simplified, but patient-specific medical history and biology are not accounted for, reducing treatment effectiveness
Solution Approach 1:
The patent introduces dynamic customization capabilities where formulation parameters (dose, concentration, substrate type, suspension properties) can be adjusted based on patient-specific data. This dynamic approach allows the manufacturing system to transition from static standardized formulations to adaptive personalized formulations, maintaining manufacturing efficiency while improving treatment effectiveness.
Solution Approach 2:
The invention applies local quality by tailoring specific formulation attributes to individual patient characteristics. Different patients receive formulations with locally optimized properties such as dose strength, flavor, texture, and administration method based on their medical history, biology, and preferences, thereby enhancing treatment effectiveness without completely abandoning standardized manufacturing processes.
3Measurement precision
If thixotropic suspension is used to deliver precise doses, then dosing accuracy is improved, but the formulation requires controlled pressure application and may have stability concerns
Solution Approach 1:
The patent utilizes thixotropic phase transition properties where the suspension maintains a semi-solid gel state at rest for stability and precision dosing, then transitions to a liquid state under applied pressure for easy administration. This phase transition capability allows the formulation to simultaneously achieve measurement precision through controlled dispensing while maintaining reliability through stable storage conditions.
Solution Approach 2:
The thixotropic carrier medium acts as an intermediary between the solid substrate and liquid suspension states. It provides a stable matrix that holds precise doses until administration, then transforms under pressure to enable delivery. This intermediary property resolves the contradiction by providing both the stability needed for precision dosing and the flow properties needed for reliable administration.
4Adaptability or versatility
If active ingredients are dispersed in liquid carrier, then dosing flexibility is improved, but microbial activity increases and shelf stability decreases
Solution Approach 1:
The patent employs phase transition between gel and liquid states to resolve the stability-flexibility contradiction. The thixotropic suspension remains in a semi-solid gel phase during storage, suppressing microbial activity and maintaining shelf stability. Upon application of controlled pressure during administration, it transitions to a liquid phase, enabling dosing flexibility and easy delivery. This temporal separation of states addresses both concerns.
Solution Approach 2:
The invention applies local quality by maintaining different physical states in different spatial and temporal contexts. During storage, the formulation exists as a stable semi-solid gel with suppressed microbial activity. During administration, localized pressure application induces liquid-like flow properties. This local quality approach allows the same formulation to simultaneously achieve shelf stability and dosing flexibility under different conditions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables precise, stable, and patient-specific delivery of active ingredients, reducing microbial activity and promoting adherence by providing a palatable, shelf-stable solid assembly that minimizes pill burden and improves treatment efficacy.
Implementation Method 1
the thixotropic suspension can be formulated from ingredients generally recognized as safe, made from a variety of digestible proteins, fats, plant fibers, polysaccharides, starches, hydrocolloid, edible waxes, or any of these materials that form a gel or SOL matrix, such that it returns to a semi-solid state at rest, and liquifies under pressure
Data Source
AI summary
The presently disclosed subject matter is directed to a system and method of preparing personalized nutritional and/or pharmaceutical formulations using additive manufacturing technology. Active pharmaceutical or dietary supplement ingredients are suspended in thixotropic stable carrier medias. The thixotropic suspensions are deposited onto a surface of a solid substrate, which can be a snack bar or small wafer used as a mechanical carrier. The disclosed system enables each additive active ingredient to be variably dosed based on a formula that is determined for each specific individual and manufactured on demand. Once the active ingredients are deposited on substrate, the entire assembly can be enrobed with one or more edible solid coatings to seal the active ingredients and provide taste-masking agent characteristics to the assembly.



